Economic burden of ventilator associated pneumonia in a developing country by Alp, E et al.
POSTER PRESENTATION Open Access
Economic burden of ventilator associated
pneumonia in a developing country
E Alp
1*, G Kalin
2, R Coskun
2, M Sungur
2, M Guven
2, M Doganay
2
From International Conference on Prevention & Infection Control (ICPIC 2011)
Geneva, Switzerland. 29 June – 2 July 2011
Introduction / objectives
There is limited data about the economic burden of
ventilator associated pneumonia (VAP) in developing
countriesTo investigate incidence, risk factors, etiologi-
cal agents, antimicrobial susceptibility rates and eco-
nomic burden of VAP in a medical intensive care unit
(MICU) of a developing country.
Methods
All patients on mechanical ventilation were followed up
during one year in MICU.
Results
During the one-year period, 159 patients were followed
up.Mean age was 61.82±16.81. VAP developed in 96
(60%) patients with 37.2/1000 ventilation days.The mean
APCAHE II score was 24.32±5.94, and there was no dif-
ference between VAP and non-VAP patients.Median
mechanical ventilation days for non-VAP patients were
3 days (1-15 days).Mortality rate for non-VAP patients
was 88.5%, and the median time for death was 4th day
of hospitalization.Median time for VAP development
was 5.5 days (2-25 days).Acinetobacter baumannii (42%)
and Pseudomonas aeruginosa (20%) were the most com-
mon pathogens.All microorganisms were multi-resistant.
Imipenem resistance of A.baumannii and P.aeruginosa
was 92% and 71%, respectively.The most significant risk
factors for VAP were stay in hospital before MICU
(OR:3.11) and length of stay in MICU (1.47). Mortality
rate for VAP-patients was 80% and there was no statisti-
c a l l yd i f f e r e n c eb e t w e e nt h em o r t a l i t yr a t e so fV A Pa n d
non-VAP patients.Median total cost of non-VAP
patients in ICU was 2315 Euro, whereas it was 6308
Euro in VAP patients. Also, cost of ICU (253&908
Euro), antibiotics (230&810 Euro), laboratory (370&979
Euro) and clinical (371&878 Euro) were higher in VAP
patients.
Conclusion
The cost of VAP is approximately three-fold higher than
non-VAP patients. Infection control standards should be
assessed and rigorously reinforced in “limited-resources”
countries.
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